Standard human chorionic gonadotropin versus double trigger for final oocyte maturation results in different granulosa cells gene expressions: a pilot study

Haas, Jigal; Ophir, Libby; Machtinger, Ronit; Yung, Yuval; Orvieto, Raoul; Hourvitz, Ariel

doi:10.1016/j.fertnstert.2016.06.002

Cited by 50 publications

(44 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…hCG administration alone also does not produce FSH activity, while GnRH agonist releases an endogenous FSH and LH surge, resulting in a more physiologic response. In vitro studies have highlighted the role of FSH in oocyte maturation [3], via the increased production of epiregulin (Ereg) and amphiregulin (Areg) [27], members of the epidermal growth factor-like (EGF) family, which have been shown to mediate the LH signal and participate in cumulus expansion and oocyte maturation [28]. This has been confirmed in vitro experiments, where Ereg and Areg presence in maturation medium helps to improve the maturation rate of human GV oocytes [29].…”

Section: Discussionmentioning

confidence: 99%

Dual-Trigger Improves the Outcomes of in Vitro Fertilization Cycles in Older Patients with Diminished Ovarian Reserve: a retrospective cohort study

Chern

Tsui

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Dual-trigger for final oocyte maturation has been applied on the women with poor ovarian response or diminished ovarian reserve. However, the results were controversial. The Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number (POSEIDON) stratification is a set of newly established criteria for low prognosis patients. The aim of this study was to examine the effectiveness of dual trigger for final oocyte maturation on the in vitro fertilization (IVF) outcomes of patients who fulfill the POSEIDON group 4 criteria.Methods: This retrospective cohort study investigated 384 cycles fulfilling the POSEIDON group 4 criteria. The patients underwent IVF treatment using the gonadotropin-releasing hormone (GnRH) antagonist protocol. The study group contained 194 cycles that received dual trigger (human chorionic gonadotropin [hCG] plus GnRH agonist) for final oocyte maturation. The control group included 114 cycles where final oocyte maturation was performed with only hCG. Baseline characteristics and cycle parameters, as well as IVF outcomes of both groups were compared.Results: Baseline characteristics were similar between the dual trigger group and the control group. In terms of IVF outcomes, the dual trigger group demonstrated significantly higher number of retrieved oocytes, metaphase II oocytes, fertilized oocytes, day-3 embryos, and top-quality day-3 embryos. A statistically significant improvement in clinical pregnancy rate and live birth rate was also observed in the dual trigger group. Regardless of whether the patients were aged < 40 or ≥ 40 years, those receiving dual trigger had increased numbers of oocytes retrieved, fertilized oocytes, day-3 embryos, top-quality day-3 embryos than those with hCG-only trigger. Clinical pregnancy rate and live birth rate were significantly increased in the < 40-year old group whilst not significantly increased in those ≥ 40 years.Conclusions: Our data suggests that dual trigger for final oocyte maturation might improve clinical pregnancy rates and live birth rates of IVF cycles in patients fulfilling the POSEIDON group 4 criteria.

show abstract

Section: Discussionmentioning

confidence: 99%

Dual-Trigger Improves the Outcomes of in Vitro Fertilization Cycles in Older Patients with Diminished Ovarian Reserve: a retrospective cohort study

Chern

Tsui

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Reduced expression of Cx43 at oocyte retrieval was associated with improved oocyte quality [54]. Double trigger with GnRH agonist and HCG reduced Cx43 mRNA CC expression and improved oocyte and embryo quality [55]. It is not clear whether increased or decreased Cx43 CC mRNA 43 expression is associated with oocyte quality.…”

Section: Gap Junction Communicationmentioning

confidence: 99%

Luteinizing Hormone Action in Human Oocyte Maturation and Quality: Signaling Pathways, Regulation, and Clinical Impact

Arroyo

Kim²,

Yeh

2020

Reprod. Sci.

View full text Add to dashboard Cite

The ovarian follicle luteinizing hormone (LH) signaling molecules that regulate oocyte meiotic maturation have recently been identified. The LH signal reduces preovulatory follicle cyclic nucleotide levels which releases oocytes from the first meiotic arrest. In the ovarian follicle, the LH signal reduces cyclic nucleotide levels via the CNP/NPR2 system, the EGF/EGF receptor network, and follicle/oocyte gap junctions. In the oocyte, reduced cyclic nucleotide levels activate the maturation promoting factor (MPF). The activated MPF induces chromosome segregation and completion of the first and second meiotic divisions. The purpose of this paper is to present an overview of the current understanding of human LH signaling regulation of oocyte meiotic maturation by identifying and integrating the human studies on this topic. We found 89 human studies in the literature that identified 24 LH follicle/oocyte signaling proteins. These studies show that human oocyte meiotic maturation is regulated by the same proteins that regulate animal oocyte meiotic maturation. We also found that these LH signaling pathway molecules regulate human oocyte quality and subsequent embryo quality. Remarkably, in vitro maturation (IVM) prematuration culture (PMC) protocols that manipulate the LH signaling pathway improve human oocyte quality of cultured human oocytes. This knowledge has improved clinical human IVM efficiency which may become a routine alternative ART for some infertile patients.

show abstract

“…Amphiregulin expression was 2.3-fold higher in mural granulosa cells in the GnRHa group, although not in follicular fluid ( 213 ). Expression of amphiregulin and epiregulin were both increased more than twofold in patients receiving both GnRHa and hCG in comparison with hCG alone ( 13 ). Expression of pigment epithelium-derived factor (an antiangiogenic factor secreted from granulosa cells) was also increased 1.5-fold, whereas cumulus cell conexin43 was reduced by 30% in the GnRHa-supplemented group ( 13 ).…”

Section: Endocrine Requirements For Oocyte Maturation and Ovulationmentioning

confidence: 99%

“…GnRHa induces endogenous gonadotropin (LH and FSH) release from the pituitary gland and is a safer option, particularly in women at high risk of OHSS ( 12 ). Unfortunately, owing to the induction of a shorter duration of LH exposure, the luteal phase is more dysfunctional following GnRHa than hCG, and thus in recent years, there has been an interest in combining the better safety profile of GnRHa with a small dose of hCG to improve pregnancy rates, in so-called “double” or “dual” trigger protocols ( 13 , 14 ). Although not in common clinical use, recombinant LH (rLH) has also been trialed as a possible alternative to hCG for inducing oocyte maturation ( 15 ).…”

mentioning

confidence: 99%

Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment

2018

View full text Add to dashboard Cite

Infertility affects one in six of the population and increasingly couples require treatment with assisted reproductive techniques. In vitro fertilization (IVF) treatment is most commonly conducted using exogenous FSH to induce follicular growth and human chorionic gonadotropin (hCG) to induce final oocyte maturation. However, hCG may cause the potentially life-threatening iatrogenic complication “ovarian hyperstimulation syndrome” (OHSS), which can cause considerable morbidity and, rarely, even mortality in otherwise healthy women. The use of GnRH agonists (GnRHas) has been pioneered during the last two decades to provide a safer option to induce final oocyte maturation. More recently, the neuropeptide kisspeptin, a hypothalamic regulator of GnRH release, has been investigated as a novel inductor of oocyte maturation. The hormonal stimulus used to induce oocyte maturation has a major impact on the success (retrieval of oocytes and chance of implantation) and safety (risk of OHSS) of IVF treatment. This review aims to appraise experimental and clinical data of hormonal approaches used to induce final oocyte maturation by hCG, GnRHa, both GnRHa and hCG administered in combination, recombinant LH, or kisspeptin. We also examine evidence for the timing of administration of the inductor of final oocyte maturation in relationship to parameters of follicular growth and the subsequent interval to oocyte retrieval. In summary, we review data on the efficacy and safety of the major hormonal approaches used to induce final oocyte maturation in clinical practice, as well as some novel approaches that may offer fresh alternatives in future.

show abstract

Standard human chorionic gonadotropin versus double trigger for final oocyte maturation results in different granulosa cells gene expressions: a pilot study

Cited by 50 publications

References 49 publications

Dual-Trigger Improves the Outcomes of in Vitro Fertilization Cycles in Older Patients with Diminished Ovarian Reserve: a retrospective cohort study

Dual-Trigger Improves the Outcomes of in Vitro Fertilization Cycles in Older Patients with Diminished Ovarian Reserve: a retrospective cohort study

Luteinizing Hormone Action in Human Oocyte Maturation and Quality: Signaling Pathways, Regulation, and Clinical Impact

Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment

Contact Info

Product

Resources

About